From Name:
From Email:
To Name:
To Email:

Optional Message:


Should pharma be criticized for investing too much in fighting cancer?

from Forbes

Earlier in the year, Helen Thomas of Wall Street Journal wrote on the “Heard on the Street” column about the large and highly concentrated investments that the biopharmaceutical industry is making in oncology research. Citing data from a Barclays analysis, Thomas voiced the following concern. “A question arises over where R&D dollars are being allocated. Barclays says that one-third of spending is going into oncology and inflammation, despite these areas accounting for less than 17 percent of projected revenue. New drugs don’t necessarily cannibalize sales of existing treatments. But if R&D spending is becoming more concentrated, firms may be swapping development risk for commercial and marketing risk.” more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063